Venture Certified
| 연구개발유형 | 2022-11-09 ~ 2025-11-08 | 20221110020002 | 2022-11-09 |
| 연구개발유형 | 2025-11-09 ~ 2028-11-08 | 20251104020004 | 2022-11-09 |
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.0B | 0.0B | 0.0B |
| Operating Profit | -3.8B | -4.6B | -3.4B |
| Net Profit | -3.0B | -2.5B | -0.7B |
| Total Assets | 6.8B | 4.9B | 4.2B |
| Total Liabilities | 0.3B | 0.1B | 0.0B |
| Total Equity | 6.4B | 4.9B | 4.1B |
Operating Loss: Op. profit -4B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+4pp YoY)
- 0.0%
▲ 4.4%
▲ 350.6%
▼ 33.0%
| Name | Position | Role |
|---|---|---|
| 이헌주 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "충청북도 청주시",
"ceo_name": "이헌주",
"certificate": [
{
"cert_number": "20221110020002",
"changes": "",
"disclosure_date": "2022-11-10",
"first_cert_date": "2022-11-09",
"no": "1",
"type": "연구개발유형",
"valid_period": "2022-11-09 ~ 2025-11-08"
},
{
"cert_number": "20251104020004",
"changes": "",
"disclosure_date": "2025-11-04",
"first_cert_date": "2022-11-09",
"no": "2",
"type": "연구개발유형",
"valid_period": "2025-11-09 ~ 2028-11-08"
}
],
"company_name": "(주)카바이오테라퓨틱스",
"corp_no": "150111-*******",
"financials": {
"2022": {
"capital_stock": 119952000,
"cost_of_sales": 0,
"current_assets": 341061000,
"current_liabilities": 4735000,
"gross_profit": 0,
"net_income": -70904000,
"net_income_bs": -70904000,
"non_current_assets": 78536000,
"non_current_liabilities": 0,
"non_operating_expenses": 1000000,
"non_operating_income": 272776000,
"operating_profit": -342680000,
"revenue": 0,
"sga_expenses": 342680000,
"total_assets": 419597000,
"total_equity": 414862000,
"total_liabilities": 4735000
},
"2023": {
"capital_stock": 445953000,
"cost_of_sales": 0,
"current_assets": 307970000,
"current_liabilities": 5613000,
"gross_profit": 0,
"net_income": -253668000,
"net_income_bs": -253668000,
"non_current_assets": 184838000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 205620000,
"operating_profit": -459288000,
"revenue": 0,
"sga_expenses": 459288000,
"total_assets": 492808000,
"total_equity": 487195000,
"total_liabilities": 5613000
},
"2024": {
"capital_stock": 486610000,
"cost_of_sales": 0,
"current_assets": 489793000,
"current_liabilities": 33324000,
"gross_profit": 0,
"net_income": -296608000,
"net_income_bs": -296608000,
"non_current_assets": 188454000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 86927000,
"operating_profit": -383535000,
"revenue": 0,
"sga_expenses": 383535000,
"total_assets": 678247000,
"total_equity": 644923000,
"total_liabilities": 33324000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "항암 CAR-T 면역세포치료제 개발",
"phone": "010-4816-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 6/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Not Collected | Not Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |